third quarter 2026
Filed Nov 4, 2026Chiron reported a quarterly net loss attributable to common stockholders of $8.9 million, while FFO and Core FFO per share and unit declined from the comparable prior-year period as the company advances its seniors housing pivot and pursues an outpatient medical portfolio disposition.
Third-quarter total revenue and resident fees increased from the comparable prior-year period, and Outpatient Medical same-property cash NOI grew +1.6%. However, net loss attributable to common stockholders widened to $8.9 million, FFO per share and unit declined to $0.50, Core FFO per share and unit declined to $0.75, and leverage increased to 41.2% of total gross assets.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Three months ended September 30, 2026 rental revenueGAAP | $33.52M | – | – |
| Three months ended September 30, 2026 resident fees and servicesGAAP | $6.24M | – | – |
| Three months ended September 30, 2026 other incomeGAAP | $581K | – | – |
| Three months ended September 30, 2026 total revenueGAAP | $40.34M | – | – |
| Three months ended September 30, 2026 general and administrative expenseGAAP | $7.70M | – | – |
| Three months ended September 30, 2026 operating expensesGAAP | $14.13M | – | – |
| Three months ended September 30, 2026 depreciation expenseGAAP | $11.03M | – | – |
| Three months ended September 30, 2026 amortization expenseGAAP | $5.14M | – | – |
| Three months ended September 30, 2026 interest expenseGAAP | $8.31M | – | – |
| Three months ended September 30, 2026 total expensesGAAP | $46.32M | – | – |
| Three months ended September 30, 2026 income before other (expense) incomeGAAP | −$5.98M | – | – |
| Three months ended September 30, 2026 loss on sale of investment propertiesGAAP | −$259K | – | – |
| Three months ended September 30, 2026 equity income (loss) from unconsolidated joint venturesGAAP | $505K | – | – |
| Three months ended September 30, 2026 net lossGAAP | −$5.74M | – | – |
| Three months ended September 30, 2026 net loss attributable to common stockholdersGAAP | −$8.86M | – | – |
| Three months ended September 30, 2026 net loss attributable to common stockholders per share – basic and dilutedGAAP | $(0.67) | – | – |
| Three months ended September 30, 2026 FFO attributable to common stockholders and noncontrolling interestnon-GAAP | $7.28M | – | – |
| Three months ended September 30, 2026 FFO attributable to common stockholders and noncontrolling interest per share and unitnon-GAAP | $0.50 | – | – |
| Three months ended September 30, 2026 Core FFO attributable to common stockholders and noncontrolling interestnon-GAAP | $10.86M | – | – |
| Three months ended September 30, 2026 Core FFO attributable to common stockholders and noncontrolling interest per share and unitnon-GAAP | $0.75 | – | – |
| Three months ended September 30, 2026 FAD attributable to common stockholders and noncontrolling interestnon-GAAP | $7.13M | – | – |
| Three months ended September 30, 2026 EBITDArenon-GAAP | $19.88M | – | – |
| Three months ended September 30, 2026 Adjusted EBITDArenon-GAAP | $22.96M | – | – |
| Three months ended September 30, 2026 NOInon-GAAP | $26.93M | – | – |
| Three months ended September 30, 2026 Cash NOInon-GAAP | $26.89M | – | – |
| Three months ended September 30, 2026 Same-Property Cash NOInon-GAAP | $24.93M | – | – |
| Outpatient Medical portfolio third quarter same-property cash NOI growthnon-GAAP | +1.6% | – | +1.6% on a year-over-year basis |
| Nine months ended September 30, 2026 total revenueGAAP | $118.1M | – | – |
| Nine months ended September 30, 2026 net incomeGAAP | $68.2M | – | – |
| Nine months ended September 30, 2026 net income attributable to common stockholdersGAAP | $53.68M | – | – |
| Nine months ended September 30, 2026 net income attributable to common stockholders per share – basic and dilutedGAAP | $4.06 | – | – |
| Nine months ended September 30, 2026 FFO attributable to common stockholders and noncontrolling interestnon-GAAP | $34.08M | – | – |
| Nine months ended September 30, 2026 Core FFO attributable to common stockholders and noncontrolling interestnon-GAAP | $41.98M | – | – |
| Nine months ended September 30, 2026 FAD attributable to common stockholders and noncontrolling interestnon-GAAP | $32.16M | – | – |
| Nine months ended September 30, 2026 EBITDArenon-GAAP | $68.3M | – | – |
| Nine months ended September 30, 2026 Adjusted EBITDArenon-GAAP | $74.26M | – | – |
| Nine months ended September 30, 2026 NOInon-GAAP | $85.64M | – | – |
| Nine months ended September 30, 2026 Cash NOInon-GAAP | $85.81M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
second half of 2028 and 2029 outlook
- NoteThe Riviera: management expects stabilization at a yield-on-cost of greater than 7% in the second half of 2028.
- NoteThe Pinnacle: management expects stabilization at a yield-on-cost of greater than 7% in 2029.
What drove it
- The Company is actively pursuing the disposition of its outpatient medical portfolio and has engaged a broker to facilitate the process.
- The Outpatient Medical portfolio had 4.6 million leasable square feet, $101 million of annualized Cash NOI, a weighted average lease term of 4.6 years, weighted average annual base rent escalations of 2.2%, and a 93.6% leased occupancy rate at quarter end.
- The Landing averaged 95.1% occupancy for the quarter ended September 30, 2026, an increase of 1.8% relative to occupancy as of June 30, 2026.
- The Riviera averaged 25.6% occupancy for the quarter ended September 30, 2026, an increase of 2.3% relative to occupancy as of June 30, 2026.
- The Company acquired a Reston, Virginia land parcel zoned for a seniors housing community for a purchase price of $15.4 million in September 2026.
- The Company completed the acquisition of The Pinnacle in October 2026 for a purchase price of $173.2 million, increasing the SHOP portfolio to three communities totaling 467 homes.
Concerns
- Reported quarterly net loss attributable to common stockholders was $8.9 million, or $0.67 per share, compared with net loss of $6.0 million, or $0.45 per share, in the comparable prior-year period.
- FFO attributable to common stockholders and noncontrolling interest per share and unit was $0.50, compared with $1.00 in the comparable prior-year period.
- Core FFO attributable to common stockholders and noncontrolling interest per share and unit was $0.75, compared with $1.12 in the comparable prior-year period.
- General and administrative expenses of $7.7 million included $2.0 million of Severance and Transition Related Expenses associated with the strategic pivot to Seniors Housing.
- The Riviera averaged 25.6% occupancy and The Pinnacle had spot occupancy of 30.9% as of September 30, 2026.
- White Rock's cure amount was approximately $2.6 million, payable over time from available cash generated by hospital operations, with any remaining balance due no later than five years following the effective date.
What to watch
- Progress, timing, and successful completion of the outpatient medical portfolio disposition process.
- The Riviera lease-up toward management's expected stabilization at a yield-on-cost of greater than 7% in the second half of 2028.
- The Pinnacle lease-up following its October 2026 acquisition and management's expected stabilization at a yield-on-cost of greater than 7% in 2029.
- Leverage following the increase to 41.2% of total gross assets at September 30, 2026.
- The use of proceeds from future disposition activity and the Company's ability to redeploy capital into its seniors housing pipeline.
Balance sheet and cash flow
- Cash and cash equivalents were $13,451 (in thousands) as of September 30, 2026, compared with $9,084 (in thousands) as of December 31, 2025.
- Restricted cash was $2,448 (in thousands) as of September 30, 2026, compared with $2,805 (in thousands) as of December 31, 2025.
- Consolidated debt outstanding, including borrowings on the credit facility and notes payable, both net of unamortized debt issuance costs, was $661.7 million at September 30, 2026.
- Leverage was 41.2% of total gross assets at September 30, 2026, compared to 39.9% as of June 30, 2026.
- Total debt carried a weighted average interest rate of 4.5%, a weighted average remaining term of 3.4 years, and 75% fixed rate debt as of September 30, 2026.
- The Company has no debt maturities in 2026 or 2027.
- Total assets were $1,398,956 (in thousands) as of September 30, 2026, compared with $1,242,465 (in thousands) as of December 31, 2025.
- Total liabilities were $718,718 (in thousands) as of September 30, 2026, compared with $712,400 (in thousands) as of December 31, 2025.
- Total equity was $680,238 (in thousands) as of September 30, 2026, compared with $530,065 (in thousands) as of December 31, 2025.
Analysis
Chiron reported third-quarter total revenue of $40,335 (in thousands), compared with $37,229 (in thousands) in the comparable prior-year period. Rental revenue was $33,515 (in thousands), compared with $37,036 (in thousands), while resident fees and services were $6,239 (in thousands) versus $— (in thousands). The addition of resident fees reflects the developing seniors housing operating portfolio, while the outpatient medical portfolio remained a material operating base with $101 million of annualized Cash NOI and 93.6% leased occupancy at quarter end.
Profitability weakened in the quarter. Net loss attributable to common stockholders was $(8,863) (in thousands), or $(0.67) per basic and diluted share, compared with $(6,001) (in thousands), or $(0.45), in the comparable prior-year period. FFO attributable to common stockholders and noncontrolling interest declined to $7,280 (in thousands), or $0.50 per share and unit, from $14,530 (in thousands), or $1.00. Core FFO was $10,860 (in thousands), or $0.75 per share and unit, versus $16,242 (in thousands), or $1.12. General and administrative expense was $7,704 (in thousands), including $2.0 million of Severance and Transition Related Expenses.
Property-level indicators were mixed. Third-quarter Same-Property Cash NOI was $24,932 (in thousands), compared with $24,529 (in thousands), and the Company stated that Outpatient Medical same-property cash NOI growth was +1.6% year over year, in line with management expectations. The Landing averaged 95.1% occupancy, but newer communities remain in early lease-up: The Riviera averaged 25.6% occupancy and The Pinnacle had 30.9% spot occupancy at September 30, 2026. The Company completed the $173.2 million Pinnacle acquisition in October 2026, expanding SHOP to three communities totaling 467 homes.
The capital structure warrants close attention during the portfolio transition. Consolidated debt outstanding was $661.7 million and leverage was 41.2% of total gross assets, compared to 39.9% as of June 30, 2026. Total debt had a 4.5% weighted average interest rate, a 3.4-year weighted average remaining term, and 75% fixed-rate debt, with no maturities in 2026 or 2027. Cash and cash equivalents were $13,451 (in thousands) at September 30, 2026.
The release did not provide quantitative revenue, earnings, FFO, or capital guidance. Its only quantified forward operating targets concern stabilization at a yield-on-cost of greater than 7% for The Riviera in the second half of 2028 and for The Pinnacle in 2029. Execution on the medical portfolio disposition, capital redeployment, and lease-up of the new seniors housing assets are the central reported operating milestones.
Management, verbatim
We continue to make meaningful progress executing our strategy, including our efforts to monetize the outpatient medical portfolio. We are encouraged by the strength of the market for high-quality medical office assets and the level of investor interest we have seen. At the same time, we continue to expand our seniors housing platform and are building a growing pipeline of attractive investment opportunities that we believe can position Chiron to thoughtfully redeploy capital and drive long-term growth.
Mark Decker, Jr., Chief Executive Officer and President
Not in the filing
stated, not guessed- Quarterly operating cash flow was not reported.
- Quarterly free cash flow was not reported.
- Gross margin was not reported.
- Operating income was not reported as a line item.
- Segment revenue was not reported for SHOP or the Outpatient Medical portfolio.
- Quantitative full-year or quarterly guidance for revenue, FFO, Core FFO, expenses, tax rate, capital spending, or dispositions was not reported.
- Prior outlook was not provided, so no actual-versus-prior-guidance comparison is available.
- Common dividend declaration, common dividend per share, share repurchases, and capital-return activity were not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.